Compositions and methods of treatment of cancer

• US 20030130293A1
• Filed: 09/05/2002
• Published: 07/10/2003
• Est. Priority Date: 09/05/2001
• Status: Active Grant

• Current Assignee: Minerva Biotechnologies Corporation
• Original Assignee: Minerva Biotechnologies Corporation
• Inventors: Bamdad, Cynthia C.
• Granted Patent: US 8,349,853 B2
• Time in Patent Office: Days
• US Class Current: 514/266.31
• CPC Class Codes: A61K 31/17 having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine isoureas, isothioureas A61K31/155; sulfonylureas A61K31/64
• CPC Class Codes: A61K 31/401 Proline; Derivatives thereof, e.g. captopril
• CPC Class Codes: A61K 31/403 condensed with carbocyclic rings, e.g. carbazole
• CPC Class Codes: A61K 31/475 having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine vincamine A61K31/4375
• CPC Class Codes: A61K 31/517 ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• CPC Class Codes: A61K 31/55 having seven-membered rings, e.g. azelastine, pentylenetetrazole
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

This invention generally relates to compositions and methods for cancer treatment and, in particular, to compositions able to interact (e.g., bind to) with MUC1 growth factor receptor or its ligands, and methods for treating the same. The invention also relates to assays or use of such compositions for the treatment of patients susceptible to or exhibiting symptoms characteristic of cancer or tumorigenesis. Other compositions of the present invention useful for the treatment or prevention of cancer or tumorigenesis include homologs, analogs, derivatives, enantiomers or functional equivalents. The present compositions can also be packaged in kits in some cases.

Claims

1. A composition, comprising a structure:

2. A composition, comprising a structure:

3. A composition, comprising a structure:

4. A composition, comprising a structure:

5. A composition, comprising a structure:

6. A composition, comprising a structure:

7. A composition, comprising a structure:

8. A composition, comprising a structure:

9. A composition, comprising a structure:

10. A composition, comprising a structure:

11. A composition, comprising a structure:

12. A composition, comprising a structure:

13. A composition, comprising a structure:

14. A composition, comprising a structure:

15. A composition, comprising a structure:

16. A method, comprising:

treating a human patient susceptible to or exhibiting symptoms of a cancer characterized by aberrant expression of MUC1, by administering to the patient a therapeutically effective amount of a composition comprising a structure;

wherein T comprises an alkyl group having at least two carbon atoms,

A¹, A², A³, and A⁴ are each independently selected from the group consisting of H and a halogen,

R¹, R², R⁴, R¹¹, R¹², R¹³, R¹⁴, and R¹⁵ each independently comprise at least one atom, and

the patient is not otherwise indicated for treatment for a cancer characterized by aberrant expression of hedgehog.

17. A method, comprising:

treating a human patient susceptible to or exhibiting symptoms of a cancer characterized by aberrant expression of MUC1, by administering to the patient a therapeutically effective amount of a composition comprising a structure;

wherein Q comprises a chemical bond or an alkyl group,

A¹, A², A³, and A⁴ are each independently selected from the group consisting of H and a halogen,

R¹, R², R⁴, R¹¹, R¹², and R¹³ each independently comprise at least one atom, and

the patient is not otherwise indicated for treatment for a cancer characterized by aberrant expression of hedgehog.

18. A composition, comprising a structure:

19. A composition, comprising a structure:

20. A method, comprising:

treating a human patient susceptible to or exhibiting symptoms of a cancer characterized by aberrant expression of MUC1, by administering to the patient a therapeutically effective amount of a composition comprising a structure;

wherein A¹, A², A³, and A⁴ are each independently selected from the group consisting of H and a halogen,

J comprises a chemical bond or at least one atom,

R², R³, R¹¹, R¹², R¹³, R¹⁴, and R¹⁵ each independently comprise at least one atom, and

the patient is not otherwise indicated for treatment for a cancer characterized by aberrant expression of hedgehog.

21. A composition, comprising a structure:

22. A composition, comprising a structure:

23. A composition, comprising a structure:

24. A composition, comprising a structure:

25. A composition, comprising a structure:

26. A composition, comprising a structure:

27. A composition, comprising a structure:

28. A composition, comprising a structure:

29. A composition, comprising a structure:

30. A composition, comprising a structure:

31. A composition, comprising a structure:

32. A composition, comprising a structure:

33. A composition, comprising a structure:

34. A composition, comprising a structure:

35. A composition, comprising a structure:

36. A composition, comprising a structure:

37. A method, comprising:

treating a human patient susceptible to or exhibiting symptoms of a cancer characterized by aberrant expression of MUC1, by administering to the patient a therapeutically effective amount of a composition comprising a structure;

Ak-Aa-Cy

wherein Ak is an alkyl group,

Cy comprises a cyclic structure,

Aa consists of a natural amino acid, and

the patient is not otherwise indicated for treatment with the composition.

38. A method, comprising:

treating a human patient susceptible to or exhibiting symptoms of a cancer characterized by aberrant expression of MUC1, by administering to the patient a therapeutically effective amount of a composition comprising a structure;

Cy¹-Aa-Cy²

wherein Cy¹ and Cy² each independently comprise a cyclic structure,

Aa consists of a natural amino acid, and

the patient is not otherwise indicated for treatment with the composition.

39. A composition, comprising a structure:

40. A method, comprising:

treating a human patient susceptible to or exhibiting symptoms of a cancer characterized by aberrant expression of MUC1, by administering to the patient a therapeutically effective amount of a composition comprising;

wherein Cy comprises a cyclic structure having at least seven members,

R³⁰, R³¹, and R³² each comprise at least one atom, and

the patient is not otherwise indicated for treatment with the composition.

41. A composition, comprising a structure:

42. A composition, comprising a structure:

43. A composition, comprising a structure: